Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
VIVJOA - official renal restriction summary
Product / population
VIVJOA - official renal restriction summary; selected source sections only, not a complete prescribing monograph.
Renal method
Source prints eGFR in mL/min without a BSA denominator; indexing is not established and is not silently relabeled.
Source revision
Prescribing information revised April 2022.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
VIVJOA: severe-renal source disagreement is not resolved by a date assumption
The RX mirror permits severe impairment; retrieved DailyMed and manufacturer safety wording do not. The mirror prints April 2024; DailyMed has a January 2026 header but an April 2022 PI revision.
What to reconcile: Hold the more permissive RX instruction for exact-label reconciliation. Do not treat header/retrieval dates as new label revisions or prescribe from the disputed extract.
VIVJOA: official recheck retains the disagreement hold
The current RX recheck remains permissive in severe impairment; the retrieved DailyMed renal section remains restrictive. Header and retrieval dates do not establish a new prescribing-information revision.
What to reconcile: Continue holding the disputed RX instruction. This release does not claim exact controlling-label reconciliation.
Official restriction rechecked; the historical mirror conflict stays open
The official label still does not recommend severe impairment or ESRD with or without dialysis. The RX mirror could not be reliably re-read in this pass.
What to reconcile: Retain the historical discrepancy and the printed renal-measure limitation. Reproductive-potential restrictions remain separate.
DailyMed / Mycovia Pharmaceuticals, Inc. · VIVJOA - official renal restriction summary; selected source sections only, not a complete prescribing monograph.
Renal method: Source prints eGFR in mL/min without a BSA denominator; indexing is not established and is not silently relabeled. Source date: Prescribing information revised April 2022. Retrieved: 2026-09-09
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No adjustment is recommended for mild/moderate impairment, defined here as MDRD eGFR 30-89 mL/min. Use in severe impairment (15-29) or ESRD (<15), with or without dialysis, is not recommended because of insufficient safety information. VIVJOA is contraindicated in females of reproductive potential and in pregnant or lactating women. The retrieved DailyMed header was updated January 8, 2026, while its PI retains an April 2022 revision. Neither retrieval nor header date establishes a newly revised renal instruction.
RDM49-official-oteseconazole-vivjoa-07fd066c0a-C1 · Source locator: Section 8.6, lines 408-410; contraindications; header update and PI revision.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.